Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions

v2.4.0.6
Composition of Certain Financial Statement Captions
9 Months Ended
Sep. 30, 2012
Business and Organization and Composition of certain Financial Statement Caption [Abstract]  
COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS

NOTE 4 COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS

 

                 

(In thousands)

  September 30,
2012
(unaudited)
    December 31,
2011
(audited)
 

Accounts receivable, net

               

Accounts receivable

  $ 19,490     $ 12,984  

Less: allowance for doubtful accounts

    (348     (440
   

 

 

   

 

 

 
    $ 19,142     $ 12,544  
   

 

 

   

 

 

 

Inventories, net

               

Finished products

  $ 17,750     $ 11,100  

Work-in process

    633       277  

Raw materials

    4,513       2,287  

Less: reserve for obsolescence

    (1,408     (325
   

 

 

   

 

 

 
    $ 21,488     $ 13,339  
   

 

 

   

 

 

 

Intangible assets, net

               

Customer relationships

  $ 19,232     $ 18,386  

In-process research and development

    11,504       10,000  

Technology

    50,211       47,100  

Product registrations

    9,638       3,895  

Tradename

    1,921       827  

Covenants not to compete

    1,758       1,560  

Other

    297       297  

Less: accumulated amortization

    (11,975     (5,335
   

 

 

   

 

 

 
    $ 82,586     $ 76,730  
   

 

 

   

 

 

 

Accrued expenses

               

Income taxes payable

  $ 649     $ 484  

Deferred revenue

    955       530  

Clinical trials

    58       7  

Professional fees

    817       632  

Employee benefits

    1,910       907  

Deferred acquisition payments, net of discount

    5,983       —    

Contingent consideration

    7,992       —    

Other

    3,430       2,396  
   

 

 

   

 

 

 
    $ 21,794     $ 4,956  
   

 

 

   

 

 

 

Other long-term liabilities

               

Contingent consideration

  $ 13,909     $ 18,002  

Deferred acquisition payments, net of discount

    3,769       —    

Deferred tax liabilities

    10,845       6,863  

Long-term debt

    3,954       —    

Other including deferred revenue

    453       578  
   

 

 

   

 

 

 
    $ 32,930     $ 25,443  
   

 

 

   

 

 

 

The change in value of the intangible assets includes the acquisitions of Farmadiet and ALS Distribuidora Limitada (“ALS”) (Refer to Note 5) and the foreign currency fluctuation between the Chilean and Mexican pesos against the US dollar at September 30, 2012 and December 31, 2011.